Nebraska Supreme Court Dismisses Medical Cannabis Preemption Challenge

Dismissal Turns on Timing, Not Constitutional Merit

The court declined to rule on whether Nebraska's medical cannabis statutes conflict with the federal Controlled Substances Act, finding the challenge premature under state justiciability doctrine. The decision leaves open the possibility of a renewed challenge once the Nebraska Department of Health and Human Services finalizes regulations and begins issuing licenses under LB 474, the Medical Cannabis Act enacted by voter initiative in November 2024.

The dismissal hinges on Nebraska's requirement that plaintiffs demonstrate concrete injury traceable to the challenged statute. The plaintiffs—a coalition of municipal officials and anti-legalization advocacy groups—argued the program's existence alone violated the Supremacy Clause by authorizing conduct criminalized under 21 U.S.C. § 812. The court wasn't convinced. Without operational harm, the argument fell short.

Justice Lindsey Miller-Lerman wrote for the majority that "speculative future conflict with federal enforcement priorities does not satisfy the case-or-controversy requirement under Article III analogues in Nebraska law." The opinion distinguished Michigan v. EPA and other federal preemption precedents, noting those cases involved active regulatory enforcement, not pre-implementation facial challenges.

Federal Preemption Doctrine Remains Unresolved in Nebraska

The dismissal leaves Nebraska's medical cannabis framework in legal limbo, with no definitive ruling on whether state-licensed cultivation and distribution violate the Supremacy Clause. Thirty-eight states now operate medical or adult-use programs despite ongoing Schedule I classification of cannabis under federal law. Nebraska became the 39th state to authorize medical use when 68% of voters approved Initiative 437 in 2024.

Preemption challenges have succeeded in blocking state cannabis programs in only two jurisdictions: a 2011 Arizona trial court ruling later overturned on appeal, and a 2015 Nebraska county court decision invalidating a prior decriminalization ballot measure. Both rulings turned on narrow interpretations of state constitutional provisions, not direct Supremacy Clause analysis.

Plaintiffs in the current case—including Lancaster County Sheriff Terry Wagner and Families Against Marijuana Abuse—relied on Gonzales v. Raich, the 2005 Supreme Court decision upholding federal authority to prosecute intrastate cannabis activity under the Commerce Clause. The Nebraska Supreme Court didn't reach the Raich question. It noted that "federal enforcement discretion and state authorization are distinct inquiries."

The absence of federal prosecution in 38 other medical cannabis states doesn't immunize Nebraska's program from preemption scrutiny, but it does underscore the practical gap between statutory conflict and enforcement reality.

Regulatory Timeline and Operational Stakes

Nebraska DHHS must promulgate final rules for cultivation, processing, testing, and dispensing by March 1, 2027, under the statutory deadline in LB 474. The department released a draft regulatory framework in June 2026, proposing a vertically integrated licensing structure capped at 15 cultivation facilities and 60 dispensaries statewide. Public comment closed August 15.

Patients with qualifying conditions—including cancer, glaucoma, PTSD, and chronic pain—can possess up to 2.5 ounces of usable cannabis and cultivate up to six plants for personal use. They must obtain a registry identification card from DHHS and a written certification from a licensed physician. Smoking's prohibited. Edibles are capped at 10 mg THC per serving.

For context on how Nebraska's framework compares to neighboring jurisdictions, see the CannIntel topic hub on Nebraska's medical cannabis program.

Industry analysts estimate Nebraska's medical market could generate $80-120 million in annual sales by 2029, based on patient enrollment projections of 15,000-20,000 registrants. The state's 6.5% sales tax applies to medical cannabis transactions, with revenue earmarked for DHHS administrative costs and behavioral health programs under the initiative's fiscal note.

Path Forward for Renewed Legal Challenge

Plaintiffs may refile the preemption claim once DHHS issues licenses and dispensaries begin operations, likely in mid-2027. The court's opinion explicitly reserved judgment on the merits, stating that "a ripe controversy may arise when state-licensed entities engage in conduct that directly conflicts with federal enforcement actions or when the state compels participation in the regulated market."

Two procedural variables complicate the timeline. First, Nebraska's Administrative Procedure Act requires exhaustion of agency remedies before judicial review, meaning plaintiffs must challenge specific DHHS licensing decisions through the administrative appeals process. Second, the court noted that federal preemption claims may require federal-question jurisdiction in U.S. District Court rather than state court, though the opinion didn't foreclose state jurisdiction entirely.

Sheriff Wagner told the Nebraska Examiner his office would "evaluate all legal options once the program becomes operational," declining to specify whether a federal lawsuit is under consideration. The plaintiffs' attorney, James Bopp Jr., has litigated similar preemption challenges in South Dakota and Oklahoma, both dismissed on state-specific constitutional grounds unrelated to the Supremacy Clause.

The next procedural milestone: DHHS's final rule publication, expected by January 2027. License applications open 60 days after final rules take effect. First dispensary sales are projected for June 2027, at which point standing arguments evaporate and the constitutional question moves to the merits phase.